Want to see VSTM full AI Analyst Report?
Verastem (VSTM) Stock Price & Analysis
VSTM Stock Chart & Stats
- Day’s Range
- $9.16 - $9.86
- 52-Week Range
- $3.43 - $10.82
- Previous Close
- $9.85
- Volume
- N/A
- Average Volume (3M)
- 4.59M
- Market Cap
- $1.20B
- Enterprise Value
- $330.42M
- Total Cash (Recent Filing)
- $172.80M
- Total Debt (Recent Filing)
- $122.12M
- Price to Earnings (P/E)
- ―
- Beta
- 1.05
- Next Earnings
- Mar 18, 2027 (Est.)
- EPS Estimate
- -0.5
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Traction
Recurring product revenue and strong refill rates indicate growing commercial adoption of the CO-PACK rather than reliance solely on one-time milestones. The accepted blister-pack NDA and priority review may further support convenience, adherence, and continued franchise development.
Pipeline Advancement
Clinical activity across several KRAS G12D-driven cancers broadens the potential addressable opportunity beyond the current franchise. FDA alignment on a Phase 3 pancreatic trial and planned discussions in other cancers provide a clearer development path for the pipeline.
Liquidity Runway
The enlarged cash position gives Verastem time to advance pivotal development and commercial operations without an immediate funding gap. Runway into the second half of 2027 supports execution through important clinical inflection points and provides greater near-term strategic flexibility.
Bears Say
Large Losses And Cash Burn
The company is not currently self-funding: substantial operating and free-cash-flow losses require continued access to capital while clinical and commercial spending remains high. Persistent cash burn could reduce the runway faster than planned and constrain investment in pipeline opportunities.
Leverage And Funding Dependence
Meaningful leverage reduces financial flexibility while Verastem continues to report heavy losses and negative cash generation. Dependence on structured financing or additional capital can increase repayment obligations, restrict strategic choices, and expose execution plans to funding conditions.
Competitive And Regulatory Risk
The pipeline’s value depends on demonstrating differentiated efficacy, safety, and regulatory suitability in an active target class. Competing programs or evolving FDA expectations could require additional evidence, delay approvals, or weaken the commercial opportunity for VS-7375.
Verastem News
VSTM FAQ
What was Verastem’s price range in the past 12 months?
What is Verastem’s market cap?
When is Verastem’s upcoming earnings report date?
How were Verastem’s earnings last quarter?
Is Verastem overvalued?
Does Verastem pay dividends?
What is Verastem’s EPS estimate?
How many shares outstanding does Verastem have?
What happened to Verastem’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Verastem?
What is the TipRanks Smart Score and how is it calculated?
Verastem Stock Smart Score
Company Description
Verastem
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel W. Paterson
- Employees
- 102
- Website
- www.verastem.com
- Address
- 117 Kendrick Street, Needham, MA, 02494, US
Verastem (VSTM) Earnings & Revenues
VSTM Company Deck
VSTM Earnings Call
Earnings Call SentimentPositive
The call conveyed substantial positive momentum: commercial rebound with $25.1M in product revenue, strengthened liquidity via a $50M draw and $15M milestone (pro forma cash $201.4M), improved non-GAAP loss versus prior year, and rapid clinical progress for VS-7375 (enrollment completed in expansions, Fast Track for NSCLC, three Phase II studies initiated and an October data update anticipated). Notable risks remain — the company is still loss-making with high R&D spend, relies on financing to bridge to readouts, has limited prescription visibility, faces tolerability and dose-management operational challenges, and navigates a competitive/regulatory landscape. On balance, the material commercial and clinical achievements and improved financial cushion outweigh the outstanding challenges.
View all VSTM earnings summariesVSTM Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 6 | 5 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 8 | 0 | 4 |
